SCHEMBL25372012

SCHEMBL25372012

[2H]C([2H])(NC(=O)NC12CC(C(F)(F)F)(C1)C2)c1cccc(C#N)c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TRPA1 O75762 1/20 0.39
▸ CNR1 P21554 1/20 0.38
▸ MEP1A Q16819 1/20 0.37
▸ MEP1B Q16820 1/20 0.37
▸ ERCC1 P07992 1/20 0.37
▸ ERCC4 Q92889 1/20 0.37
▸ SMN1; SMN2 Q16637 1/20 0.37
▸ CLPP Q16740 1/20 0.36
▸ VNN1 O95497 3/20 0.36
▸ LMNA P02545 1/20 0.36
▸ CNR2 P34972 1/20 0.35
▸ DPP8 Q6V1X1 1/20 0.35
▸ DPP9 Q86TI2 1/20 0.35
▸ GLMN Q92990 1/20 0.35
▸ GLA P06280 1/20 0.35
▸ L3MBTL1 Q9Y468 1/20 0.35
▸ FAAH O00519 1/20 0.35
▸ NAMPT P43490 1/20 0.35
▸ PDK1 Q15118 1/20 0.34
▸ PDK2 Q15119 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30580152 1.00 TRPA1 (0.39) TRPA1CNR1MEP1AMEP1BERCC1
SCHEMBL30580137 0.90 ERCC1 (0.46) TRPA1CNR1MEP1AMEP1BERCC1
SCHEMBL25369595 0.90 ERCC1 (0.46) TRPA1CNR1MEP1AMEP1BERCC1
SCHEMBL31173727 0.85 SMN1; SMN2 (0.40) TRPA1CNR1MEP1AMEP1BERCC1
SCHEMBL25368871 0.80 EPHX2 (0.44) CNR1VNN1NAMPT
SCHEMBL25374463 0.79 EPHX2 (0.39) ERCC1ERCC4SMN1; SMN2LMNAGLA
SCHEMBL30580171 0.79 EPHX2 (0.39) ERCC1ERCC4SMN1; SMN2LMNAGLA
SCHEMBL31173726 0.77 ERCC1 (0.49) CNR1MEP1AMEP1BERCC1ERCC4
SCHEMBL25369701 0.77 ERCC1 (0.49) CNR1MEP1AMEP1BERCC1ERCC4
SCHEMBL31173732 0.76 ERCC1 (0.50) CNR1MEP1AMEP1BERCC1ERCC4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250002452-A1 BICYCLOPENTANE DERIVATIVES ANGELINI PHARMA S.P.A. (IT) 2025-01-02 — — US disclosed
EP-4479377-A1 NEW BICYCLOPENTANE DERIVATIVES Icagen, LLC (US) 2024-12-25 — — EP disclosed
WO-2023158584-A1 NEW BICYCLOPENTANE DERIVATIVES ICAGEN, LLC (US) 2023-08-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250002452-A1 BICYCLOPENTANE DERIVATIVES BICRA, C1R, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 TRPA1 1393/4885CNR1 14/4885MEP1A 407/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback